Literature DB >> 18467244

Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations.

E A Debbia1, E Maioli, S Roveta, A Marchese.   

Abstract

Rifaximin, a poorly absorbed rifamycin derivative, exhibited time-dependent bactericidal activity and at concentrations as low as 1/32 of the minimum inhibitory concentration (MIC) caused morphological alterations in both susceptible and resistant bacterial strains. Spontaneous rifaximin-resistant clones appeared with an incidence of 2.6 x 10(-7). The percentage of Escherichia coli cells cured of various plasmids ranged from: 4.5-70% (Flac), 0-18% (pBP507), 7.7-43.8% (plasmid carrying ESBL genes) and 22.4-41.6% (plasmid encoding toxin from ETEC mex264). 8.4-18.2 and <0.1-18% of Staphylococcus aureus cells were cured (plasmid-mediated penicillinase), 9.5-58.6% of Morganella morganii (ESBL), 10.6-47.1% Citrobacter freundii (ESBL), 2.3-38.7% of Proteus mirabilis (ESBL) and 14.3-66.6% of Klebsiella pneumoniae (ESBL). Rifaximin reduced plasmid transfer from donor to recipient strains by >99%. The MIC of ceftazidime was reduced (2-4 dilutions) in the presence of rifaximin (0.5 x MIC) in ESBL producing strains. Rifaximin lowered the viability and virulence of the bacteria even though they developed resistance to the compound. In conclusion, the present findings add new features to the microbiological characteristics of rifaximin and suggest that if in vivo pathogens are exposed to sub-MICs of the drug, not only are their physiological functions compromised, but gene virulence and antibiotic resistance are not fully expressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467244     DOI: 10.1179/joc.2008.20.2.186

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  22 in total

Review 1.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Davide Roccarina; Francesca Romana Ponziani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

Review 3.  Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.

Authors:  Karim M Eltawil; Marie Laryea; Kevork Peltekian; Michele Molinari
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

4.  Treatment options for covert hepatic encephalopathy.

Authors:  Nisheet Waghray; Abhijeet Waghray; Kevin Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

5.  Antibiotics for the treatment of irritable bowel syndrome.

Authors:  Robert J Basseri; Stacy Weitsman; Gillian M Barlow; Mark Pimentel
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-07

6.  Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.

Authors:  Mark Pimentel; Walter Morales; Kathleen Chua; Gillian Barlow; Stacy Weitsman; Gene Kim; Meridythe M Amichai; Venkata Pokkunuri; Emily Rook; Ruchi Mathur; Zachary Marsh
Journal:  Dig Dis Sci       Date:  2011-05-11       Impact factor: 3.199

Review 7.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

8.  High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center.

Authors:  Puneeta Tandon; Angela Delisle; Jeffrey E Topal; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

Review 9.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

10.  Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.

Authors:  Eric L Brown; Qiong Xue; Zhi-Dong Jiang; Yi Xu; Herbert L Dupont
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.